In compliance with current regulations, let us know which audience you belong to:
LM® LLLT
Light Modulation®
The power of light, cubed.
—LM® LLLT
LM® Low-level Light Therapy is a unique, light-based photobiomodulation technology. We developed and patented for medical use the technology originally employed by NASA (i.e., Low-level Laser Therapy) to treat astronauts in space.
LM® LLLT has nothing to do with Red Light Therapy (RLT), which only acts on the surface of the dermis—instead, LM® LLLT works at biological level, generating endogenous heat through powerful LEDs stimulating ATP production in cells.
Discover the Science behind LM® LLLT
No pain,
Extreme gains.
Photobiostimulation therapy enabled by LM® LLLT is a unique kind of near-infrared light therapy (NILT) that’s completely painless for the patient—yet extremely effective in managing a vast number of ocular surface conditions such as Meibomian Glands Dysfunction. Different wavelengths (Red, Blue, Yellow) are available, for different use cases.
Maximum convenience,
exceptional value.
The degree of simplicity offered by LM® LLLT technology to the operator, and the convenience hence provided to the patient benefitting from its therapy is, put simply, unmatched. This, paired with LM® LLLT exceptional efficacy in treating most ocular surface diseases (e.g., MGD, Chalazia, Blepharitis, Sjögren’s Syndrome), makes it a true game-changer.
Science told us.
It just works.
LM® LLLT has recently been studied in a piece of research that compared it directly against IPL. The study has confirmed the efficacy of LM® LLLT, proving also its superior performance against traditional IPL technologies.
Another recent scientific paper has confirmed that LM® LLLT, employed jointly with OPE® IPL, is the key factor in effectively managing the most severe cases of recalcitrant MGD-induced DED and other ocular surface diseases.
Beyond treatments, elevating refractive surgery routines.
LM® LLLT’s potential doesn’t end with direct treatment of most ocular surface diseases. Literature tells us that unresolved ocular surface disease (OSD) represents a major risk factor for suboptimal outcomes in refractive surgery (Labetoulle M. Et Al, 2019). That’s why the Espansione Ecosystem, above all through LM® LLLT, is the best option to elevate your surgery routine.
A technology
Like no other.
Operators and patients can enjoy the unique benefits of LM® LLLT technology.
- ① it’s fast—a treatment lasts 15 minutes
- ② it’s painless
- ③ it grants immediate relief to the patient
- ④ it’s easy and safe for the operator
- ⑤ It’s plug&play—it doesn’t require the operator to be constantly present during the treatment